Page last updated: 2024-08-21

evans blue and sorafenib

evans blue has been researched along with sorafenib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S	1

Other Studies

1 other study(ies) available for evans blue and sorafenib

Article	Year
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. Cancer research, 2015, Aug-01, Volume: 75, Issue:15 Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution	2015

Article

Year

Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.

Cancer research, 2015, Aug-01, Volume: 75, Issue:15

Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution

2015